David Linetsky Sells 1,716 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 1,716 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $39,897.00. Following the transaction, the senior vice president now owns 203,318 shares of the company’s stock, valued at approximately $4,727,143.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Linetsky also recently made the following trade(s):

• On Tuesday, July 16th, David Linetsky sold 1,820 shares of Phreesia stock. The shares were sold at an average price of $23.74, for a total transaction of $43,206.80.
• On Thursday, June 20th, David Linetsky sold 66 shares of Phreesia stock. The shares were sold at an average price of $19.73, for a total transaction of $1,302.18.
• On Tuesday, June 18th, David Linetsky sold 41 shares of Phreesia stock. The shares were sold at an average price of $19.20, for a total transaction of $787.20.

Phreesia Trading Up 3.9 %

Shares of Phreesia stock opened at $24.68 on Friday. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.42 billion, a PE ratio of -11.37 and a beta of 0.93. The company has a 50-day moving average of $23.72 and a two-hundred day moving average of $22.75.

Analyst Ratings Changes

PHR has been the subject of several research analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Stephens restated an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a research note on Friday, May 31st. Truist Financial upped their price objective on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $34.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.42.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Ensign Peak Advisors Inc increased its holdings in Phreesia by 3.2% in the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock valued at $477,000 after buying an additional 700 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in shares of Phreesia by 1.0% in the first quarter. Conestoga Capital Advisors LLC now owns 78,085 shares of the company’s stock valued at $1,869,000 after purchasing an additional 750 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Phreesia by 8.6% in the first quarter. ProShare Advisors LLC now owns 9,522 shares of the company’s stock valued at $228,000 after purchasing an additional 751 shares during the last quarter. Rhumbline Advisers grew its position in shares of Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock valued at $1,741,000 after purchasing an additional 853 shares during the last quarter. Finally, Swiss National Bank grew its position in shares of Phreesia by 1.0% in the first quarter. Swiss National Bank now owns 104,300 shares of the company’s stock valued at $2,496,000 after purchasing an additional 1,000 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.